TIAA Trust National Association Sells 351 Shares of Solventum Co. (NYSE:SOLV)

TIAA Trust National Association trimmed its position in Solventum Co. (NYSE:SOLV) by 6.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,280 shares of the company’s stock after selling 351 shares during the period. TIAA Trust National Association’s holdings in Solventum were worth $349,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Modus Advisors LLC purchased a new position in shares of Solventum in the fourth quarter worth approximately $25,000. Stonebridge Financial Group LLC purchased a new position in shares of Solventum during the 4th quarter worth $26,000. Crews Bank & Trust bought a new stake in shares of Solventum during the 4th quarter valued at $32,000. True Wealth Design LLC increased its stake in shares of Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares in the last quarter. Finally, Synergy Asset Management LLC bought a new position in Solventum in the 4th quarter worth $35,000.

Solventum Stock Down 1.0 %

Shares of SOLV stock opened at $74.78 on Friday. The company’s fifty day simple moving average is $75.51 and its two-hundred day simple moving average is $71.83. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The stock has a market cap of $12.94 billion and a P/E ratio of 27.19. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SOLV. The Goldman Sachs Group boosted their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Piper Sandler raised their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Wells Fargo & Company upped their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Mizuho raised their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Finally, Morgan Stanley upped their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.